Analysis of Epidemiological Data and Risk Factors for Helicobacter pylori Infection Among Children and Adolescents in Hainan Province - Scorecard - DentalSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Analysis of Epidemiological Data and Risk Factors for Helicobacter pylori Infection Among Children and Adolescents in Hainan Province

  • By

  • Yuliang Huang

  • Yanting Lv

  • Xianfeng Huang

  • Daya Zhang

  • Chen Chen

  • Shuo Zhou

  • Xiaodong Zhang

  • Shiju Chen

  • Da Li

  • Fengjiao Mao

  • Shimei Huang

  • Fan Zeng

  • Runxiang Chen

  • Yiping Du

  • Runyu Chen

  • Ying Mo

  • Qicen Yao

  • Fei Zheng

  • Chuni Han

  • Yuehong Jiang

  • Yunqian Xie

  • Feihu Bai

  • January 19, 2026

Share

Clinical Scorecard: Analysis of Epidemiological Data and Risk Factors for Helicobacter pylori Infection Among Children and Adolescents in Hainan Province

At a Glance

CategoryDetail
ConditionHelicobacter pylori infection
Key MechanismsColonization of gastric mucosa by microaerophilic, Gram-negative, spiral-shaped bacterium with helical morphology and flagella enabling survival in acidic stomach environment
Target PopulationChildren and adolescents aged 6–17 years in Hainan Province, China
Care SettingSchool-based epidemiological survey with clinical testing and questionnaire assessment

Key Highlights

  • H. pylori is a Group I carcinogen linked to chronic gastritis, peptic ulcer, gastric cancer, MALT lymphoma, GERD, and functional dyspepsia.
  • Global prevalence remains high in children and adolescents, especially in low socioeconomic and poor sanitation areas; adolescent prevalence in China reported at 24.89%.
  • Traditional PPI-based triple therapy efficacy is declining below 80% due to increasing clarithromycin resistance.

Guideline-Based Recommendations

Diagnosis

  • Use C13 urea breath test (C13-UBT) for non-invasive detection of H. pylori infection.

Management

  • Standard treatment includes PPI-based triple therapy combining PPI, clarithromycin, and amoxicillin or metronidazole.
  • Consider antibiotic resistance patterns, especially clarithromycin resistance mutations (A2143G, A2144G), when selecting therapy.

Monitoring & Follow-up

  • Monitor treatment efficacy due to declining eradication rates linked to antibiotic resistance.

Risks

  • Risk factors include close family contact, poor sanitation, high population density, and lower socioeconomic status.
  • Avoid recent use of antibiotics, PPIs, or bismuth agents before diagnostic testing to prevent false negatives.

Patient & Prescribing Data

Children and adolescents aged 6–17 years attending schools in Hainan Province

High clarithromycin resistance reduces efficacy of standard triple therapy; tailored treatment strategies may be necessary.

Clinical Best Practices

  • Obtain informed consent from parents and participants prior to testing and data collection.
  • Use stratified sampling to ensure representative epidemiological data across geographic and socioeconomic groups.
  • Administer questionnaires with parental assistance for children under 12 to ensure data accuracy.
  • Exclude patients with recent antibiotic, PPI, or bismuth use to avoid diagnostic interference.
  • Consider regional antibiotic resistance patterns when selecting eradication regimens.

Related Resources & Content

Original Source(s)

Related Content